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Transfer RNA (tRNA) activity is tightly regulated to provide a
physiological protein translation, and tRNA chemical modifications
control its function in a complex with ribosomes and messenger
RNAs (mRNAs). In this regard, the correct hypermodification of
position G37 of phenylalanine-tRNA, adjacent to the anticodon, is
critical to prevent ribosome frameshifting events. Here we report
that the tRNA-yW Synthesizing Protein 2 (TYW2) undergoes pro-
moter hypermethylation-associated transcriptional silencing in hu-
man cancer, particularly in colorectal tumors. The epigenetic loss
of TYW2 induces guanosine hypomodification in phenylalanine-
tRNA, an increase in −1 ribosome frameshift events, and down-
regulation of transcripts by mRNA decay, such as of the key cancer
gene ROBO1. Importantly, TYW2 epigenetic inactivation is linked
to poor overall survival in patients with early-stage colorectal can-
cer, a finding that could be related to the observed acquisition of
enhanced migration properties and epithelial-to-mesenchymal fea-
tures in the colon cancer cells that harbor TYW2 DNA methylation-
associated loss. These findings provide an illustrative example of
how epigenetic changes can modify the epitranscriptome and fur-
ther support a role for tRNA modifications in cancer biology.
epigenetics | transfer RNA | cancer
Coding and noncoding RNA molecules harbor chemicallymodified nucleosides that together constitute the so-called
“epitranscriptome” (1, 2). These chemical modifications are
particularly abundant in transfer RNA molecules (tRNAs), with
more than 50 different modifications described in eukaryotic
tRNAs (3–6). Modified bases in tRNA are critical for its trans-
lational function at multiple levels, including amino acid loading,
wobbling or translation efficiency, and fidelity, among others (5,
7). tRNA modifications also serve as a translational regulation
mechanism under stress conditions (4). Defects in tRNA modi-
fications or tRNA modifier enzymes are present in various hu-
man pathologies, including neurologic disorders, mitochondrial
diseases, and cancers (8–10).
The causes and roles of the tRNA modification changes ob-
served in cancer are poorly understood. One example of chemical
modifications found in tRNA that has not been studied in depth in
the context of transformed cells is the existence of wybutosine
(yW)-derived nucleosides in position G37, adjacent to the anti-
codon of phenylalanine tRNA (tRNAPhe). Highly modified pu-
rines in position 37 of various tRNAs are key for maintaining the
ribosome reading frame and ensuring translation fidelity. Con-
cretely, yW, first described in 1968 and originally called Y-base
(11), prevents −1 programmed ribosome frameshifting (PRF)
events (12) as a result of a proper stabilization of the codon-
anticodon pairing through base-stacking interaction (13). Ribo-
some frameshifts occur in sequences with a specific structure
comprising a slippery heptamer followed by a complex secondary
structure (14). The loss of yW enhances −1 PRF events in viral
sequences (12, 15), which is essential for the correct expression of
viral proteins. Ribosome frameshifting also occurs in messenger
RNA (mRNA). When ribosomes slip and alter the reading frame,
a premature stop codon usually appears, and the mRNA is de-
graded via nonsense-mediated decay (NMD) (16). Therefore,
PRF events are postulated to be an additional layer of posttran-
scriptional regulation of mRNA abundance.
An eye-opening stream of data indicating a role for the
hypermodification of position G37 in cancer occurred in the late
1970s, when various researchers highlighted in prominent pub-
lications the tumor-specific loss of the Y-base of tRNAPhe and
suggested that this phenomenon could provide a growth advantage
to these cells (17–19). The underlying mechanism has remained
unknown for the last 45 y, however. To solve this enigma, we
wondered about the presence of cancer-specific defects in the six
enzymes, TRMT5 (20) and TYW1–5 (21, 22), that act sequentially
in humans to modify the original G37 nucleotide to finally obtain
the hypermodified yW in its hydroxylated (OHyW) or peroxydated
(o2yW) form. Since transcriptional silencing associated with
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promoter CpG island hypermethylation is a frequent mechanism
of gene inactivation in transformed cells (23, 24), we interrogated
the presence of this type of epigenetic inactivation in the genes
encoding the enzymes responsible for yW derivative synthesis. We
found that TYW2 undergoes tumor-specific silencing by promoter
CpG island hypermethylation, preventing formation of the hyper-
modified forms of G37. Those cancer cells with the hypomodified
guanosine were prone to ribosome frameshifting events. Most im-
portantly, the epigenetic defect in TYW2 was associated with poor
clinical outcome of the studied colorectal cancer, an observation
that can be linked to the acquisition of enhanced cellular migration
features and epithelial-to-mesenchymal features on TYW2 loss.
Results
Promoter CpG Island Hypermethylation-Associated Transcriptional
Silencing of the tRNA-Modifying Enzyme TYW2 in Colon Cancer. To
identify epigenetic defects in the enzymes involved in generating
the hypermodified guanosine nucleotide in the tRNAPhe, we
studied the DNA methylation status of the 5′-end–associated CpG
islands of TRMT5, TYW1, TYW2, TYW3, TYW4, and TYW5 genes.
These six human enzymes were identified as involved in the dif-
ferent chemical modifications that this nucleotide undergoes from
its initial G37 form (Fig. 1A) (21, 22). Data mining of thousands of
primary tumors corresponding to all cancer types available at The
Cancer Genome Atlas (TCGA) (https://www.cancer.gov/about-nci/
organization/ccg/research/structural-genomics/tcga) did not indi-
cate the presence of TRMT5, TYW1, TYW3, TYW4 or TYW5
promoter hypermethylation events (SI Appendix, Fig. S1A and
Dataset S1). In contrast, the TYW2 promoter CpG island was
methylated in 19.03% (79 of 415) of the primary colorectal car-
cinomas available in the TCGA (Fig. 1B and Dataset S1). Beyond
colorectal tumors, the TYW2 promoter CpG island was also
commonly hypermethylated in cervical (17.37%; 45 of 259), gastric
(12.88%; 51 of 396). and uterine (12.12%; 60 of 495) carcinomas
(Fig. 1B and Dataset S1). For TYW2, as well as the other five
tRNA-modifying enzymes studied here, the promoter CpG island
was always unmethylated in all the normal human tissues studied
(Dataset S2). Data mining of the TCGA RNA-sequencing (RNA-
seq) data available in colorectal tumors showed that TYW2
hypermethylation was associated with transcript down-regulation
(Spearman rho = −0.47; P < 0.0001) (Fig. 1C). In this regard,
TYW2 was the only G37 tRNAPhe- modifying enzyme showing
RNA down-regulation in the TCGA dataset (SI Appendix, Fig. S2).
We also data mined the Sanger set of 1,001 human cancer cell
lines, in which we had recently obtained the DNA methylation
and expression profiles (25), and obtained results similar to those
observed in the TCGA cohorts (SI Appendix, Fig. S1B and
Dataset S3). In this regard, colorectal cancer cell lines were the
most frequently TYW2-hypermethylated tumor type (Fig. 1D and
Dataset S3), and TYW2 hypermethylation was also associated
with transcript down-regulation (Fig. 1E), mimicking the results
observed in the TCGA cohorts. Thus, the higher frequency of
aberrant TYW2 DNA methylation-associated transcriptional si-
lencing observed in colorectal cancer prompted us to focus our
efforts on this tumor type.
We analyzed in more detail the link between TYW2 promoter
CpG island hypermethylation and transcriptional inactivation of
the gene at the RNA and protein levels in colon cancer cell lines.
We performed bisulfite genomic sequencing of multiple clones
from SW48, HT-29, HCT-116, and SW480 cells using primers
that encompassed the transcription start site (TSS)-associated
CpG island. We observed that the 5′-end CpG island of TYW2 in
the SW48 and HT-29 cell lines was hypermethylated compared
with normal colon mucosa (Fig. 1F), whereas the HCT-116 and
SW480 cells were unmethylated (Fig. 1F). These results mim-
icked the DNA methylation patterns found by the microarray
approach used in the Sanger cell line cohort (25) (Fig. 1G).
Importantly, the TYW2 hypermethylated colon cancer cell lines
SW48 and HT-29 minimally expressed the TYW2 RNA tran-
script and protein, as determined by quantitative real-time PCR
and Western blot analysis, respectively (Fig. 1H). In contrast, the
unmethylated cell lines HCT-116 and SW480 expressed the
TYW2 transcript and protein (Fig. 1H). The use of the inhibitor
of DNA methylation 5-aza-2-deoxycytidine in the TYW2 hyper-
methylated cell lines restored its expression at the RNA and
protein levels (Fig. 1I), reinforcing the link between TYW2
promoter hypermethylation and transcriptional silencing.
TYW2 Epigenetic Silencing in Cancer Cells Mediates Loss of Hypermodified
Guanosine in tRNA and Ribosomal Frameshifting. After detecting the
presence of TYW2 CpG island hypermethylation-associated tran-
scriptional loss in colorectal cancer cell lines, we studied its con-
tribution to the chemical modification status of G37 using tRNA-
associated liquid chromatography-mass spectrometry (LC/MS)
(26). We first assessed the profile of the modified nucleosides of
G37 according to the TYW2 CpG island methylation status in the
studied colorectal cancer cell lines. We observed that the fully
hypermodified residues OHyW and o2yW were present in the
TYW2 unmethylated/expressing cells HCT-116 and SW480 (Fig.
2A), whereas the intermediate modified nucleoside imG-14, the
direct substrate of TYW2 (Fig. 1A), was absent (Fig. 2A). The
opposite scenario was observed in the TYW2 hypermethylated/si-
lenced cell lines HT-29 and SW48, which showed an accumulation
of the TYW2 substrate imG-14 and a loss of the hypermodified
OHyW and o2yW (Fig. 2A).
To further interrogate the association between TYW2 ex-
pression and the chemical modification status of G37, we gener-
ated two stable TYW2 knockout models in the unmethylated cell
lines HCT-116 and SW480 to mimic the effects of the observed
transcriptional silencing. In this approach, we used the CRISPR/
Cas9 system to generate a deletion within TYW2 gene body and
confirmed the removal of a 234-bp fragment by Sanger sequencing
(SI Appendix, Fig. S3A) and by genomic PCR (SI Appendix, Fig.
S3B). The effectiveness of the knockout was confirmed by Western
blot analysis, which showed no TYW2 protein expression in HCT-
116 and SW480 TYW2 KO cell lines (Fig. 2B). On CRISPR/Cas9-
mediated loss of TYW2 in HCT-116 and SW480, we found an
accumulation of the TYW2 substrate imG-14 and loss of hyper-
modified OHyW and o2yW (Fig. 2C), mimicking the effects of the
DNAmethylation-associated transcriptional silencing in the HT-29
and SW48 cell lines (Fig. 2A). We also performed the reverse
experiment in which we restored expression of TYW2 in the
hypermethylated/silenced cell line HT-29 by stable transfection
(Fig. 2B). The LC/MS approach resulted in the opposite scenario
as seen in the CRISPR/Cas9 deletion model: the recovery of
TYW2 expression by transfection depleted the intermediate imG-
14 nucleoside and caused the appearance of OHyW and o2yW
hypermodified residues (Fig. 2C), mimicking the pattern observed
in the TYW2 unmethylated/expressing cell lines HCT-116 and
SW480 (Fig. 2A). The modified nucleoside yW-86 was undetect-
able in all the samples studied (SI Appendix, Fig. S4), supporting
the reported kinetics of the pathway that rapidly transforms this
residue to the hypermodified OHyW and o2yW nucleosides (21).
Hypermodified guanosine at position 37 of tRNA, such as
wybutosine in yeast, is known to help maintain the reading frame
during translation by preventing −1 PRF events at mRNAs that
contain a slippery sequence (12). Thus, we wondered whether
the appearance of hypomodified yW on TYW2 epigenetic in-
activation could affect this mechanism, which preserves the proper
mRNA-to-protein translation. To investigate this phenomenon in
our human cancer cells, we used a dual luciferase reporter system
as described previously (27). In this model, Renilla and firefly lu-
ciferases are separated by the widely known slippery sequence
from HIV (28), and if ribosome slippage occurs, changing the
reading frame and inducing a premature stop codon, the firefly
activity is abolished (Fig. 2D). Using this reporter to monitor the







































reading frame maintenance of the described sequence, we found
that CRISPR/Cas9-mediated loss of TYW2 in HCT-116 and
SW480 cells provoked a significant reduction in firefly luciferase
activity (Fig. 2D). In the opposite experiment, transfection-mediated
restoration of TYW2 in the hypermethylated/silenced cell line
HT-29 increased firefly luciferase activity compared with empty
vector-transfected cells (Fig. 2D).
We also used a second programmed frameshift reporter based-
assay to evaluate the production of proteins resulting from −1
PRF events (12). In this dual glutathione S-transferase (GST)
construct, two GST coding sequences are separated by the HIV
slippery sequence and an in-frame stop codon before the second
GST (Fig. 2E). In the event of ribosome slippage and alteration of
the reading frame, this stop codon is ignored, and the second GST
is translated, generating a larger protein. These proteins can be
detected by Western blot analysis, and frameshifting frequency
can be inferred by calculating the percentage of the large protein
production (frameshift product) over the total protein production
(the sum of the dual GST/large protein and the single GST/short
protein) (Fig. 2E). Using this reporter, we observed a significant
increase in the frameshifting frequency of the TYW2 CRISPR/
Cas9 KO HCT-116 and SW480 cells compared with the TYW2
unmethylated/expressing cells (Fig. 2E). Thus, losing TYW2 and
hypermodified yW in colon cancer cells confers a phenotype prone
to ribosomal frameshifting events.
Transcriptomic Characterization of RNA Slippery Sequences and
Ribosome Frameshift on TYW2 Epigenetic Loss in Cancer Cells.
There is a balance between mRNA production and degrada-
tion that confers cellular homeostasis and adaptation. Among
Fig. 1. TYW2 promoter CpG island hypermethylation-associated transcriptional silencing in primary colorectal tumors and cancer cell lines. (A) Schematic
representation of wybutosine derivative synthesis at position G37 of human tRNAPhe. The enzymes catalyzing these reactions are shown in blue. Abbrevi-
ations for the modified G37 nucleoside are as follows: m1G, 1-methylguanosine; imG-14, 4-demethylwyosine; yW-86, 7-aminocarboxypropyl-demethylwyo-
sine; yW-72, 7-aminocarboxypropylwyosine; OHyW*, undermodified hydroxywybutosine; OHyW, hydroxywybutosine; o2yW, peroxywybutosine. (B)
Frequency of TYW2 hypermethylation in primary tumors derived from TCGA according to cancer type. (C) The presence of TYW2 methylation is significantly
associated with loss of expression of the TYW2 transcript in primary colorectal tumors from TCGA. Spearman correlation, P < 0.001. (D) Frequency of TYW2
hypermethylation in cancer cell lines derived from the Sanger panel according tumor type. (E) The presence of TYW2 methylation is significantly associated
with loss of expression of the TYW2 transcript in colorectal cancer cell lines from the Sanger panel. Spearman correlation, P < 0.001. (F) Bisulfite genomic
sequencing of TYW2 promoter CpG island in colon cancer cell lines and in normal colon. CpG dinucleotides are represented as short vertical lines; the TSS is
indicated with a black arrow. Single clones are shown for each sample. The methylation status of each CpG dinucleotide within the interrogated sequence is
denoted with a black (methylated) or white (unmethylated) square. (G) DNA methylation profile of the TYW2 promoter CpG island analyzed by the Infinium
450K DNA methylation array. Single CpG absolute methylation β-values are shown (0 to 1). Red, methylated; green, unmethylated. Data from four colon
cancer cell lines and two normal colon samples are shown. (H) TYW2 expression levels in methylated (SW48 and HT-29) and unmethylated (HCT-116 and
SW480) cancer cell lines determined by qRT-PCR (Top) and Western blot analysis (Bottom). The qRT-PCR data shown represent the mean ± SD of at least three
biological replicates and were analyzed using the unpaired two-tailed Student’s t test. ***P < 0.001. (I) Recovery of TYW2 transcript (Top) and protein
(Bottom) expression in hypermethylated colon cancer cell lines SW48 and HT-29 on use of the demethylating agent 5-aza-2’-deoxycytidine (AZA). The qRT-PCR
data shown represent the mean ± SD of at least three biological replicates and were analyzed using the unpaired two-tailed Student’s t test. ***P < 0.001.

















































the different mechanisms involved in this equilibrium, PRF may
serve as an mRNA abundance control mechanism by inducing a
premature stop codon and mRNA degradation via NMD (16).
The physiological status quo for mRNA levels is distorted in
human tumors, and we wondered whether TYW2 epigenetic loss
by generation of hypomodified guanosine and −1 PRF could
induce aberrant mRNA degradation in colon cancer.
To explore this, we performed RNA-seq in the TYW2 unme-
thylated/expressing HCT-116 cells and its derived cell line har-
boring CRISPR/Cas9-mediated loss of TYW2. We observed that
Fig. 2. TYW2 epigenetic silencing in cancer cells mediates loss of hypermodified guanosine in tRNA and impairs ribosomal reading frame maintenance. (A)
Nucleoside analysis of tRNAs by LC/MS showing that TYW2 promoter hypermethylation and transcriptional inactivation in SW48 and HT-29 cell lines are
associated with complete depletion of the fully modified wybutosine derivatives OHyW and o2yW and induce an accumulation of TYW2 substrate imG-14.
TYW2 unmethylated cell lines HCT-116 and SW480 present the fully modified residues and absence of the hypomodified intermediary imG-14. (B) Western
blots showing efficient depletion of TYW2 expression in the unmethylated colon cell lines HCT-116 and SW480 on CRISPR/Cas9-mediated deletion (Top) and
transfection-mediated recovery of TYW2 in the hypermethylated cell line HT-29 (Bottom). (C) LC/MS showing that CRISPR/Cas9 deletion of TYW2 in HCT-116
and SW480 cells provokes a complete depletion of the fully modified wybutosine (yW) derivatives OHyW and o2yW and accumulation of the TYW2 substrate
imG-14. The opposite scenario is observed on transfection-mediated recovery of TYW2 expression in HT-29 cells. WT, wild-type cells; EV, empty vector
transfected cells. (D) In vitro assay to measure PRF at an mRNA containing a slippery sequence. (Left) Schematic representation of the dual luciferase reporter
used to monitor −1 PRF events in the colon cell line models in which Renilla and firefly luciferases are separated by the slippery sequence from HIV and if
ribosome slippage occurs, the reading frame changes and induces a premature stop codon detected by diminished firefly activity. (Right) CRISPR/Cas9-me-
diated loss of TYW2 in HCT-116 and SW480 cells caused a significant reduction in firefly luciferase activity, whereas transfection-mediated recovery of TYW2
in the hypermethylated/silenced cell line HT-29 increased firefly luciferase activity. Firefly luciferase activity was compared using an unpaired two-tailed
Student’s t test. **P < 0.01. (E, Left) Schematic representation of the dual-GST reporter used to evaluate −1 PRF events in colon cancer cell lines on CRISPR/
Cas9-mediated TYW2 depletion. Two GST coding sequences are separated by the slippery sequence from HIV, and the second GST is translated only if ri-
bosome slippage occurs. (E, Middle) Representative Western blot of the reporter construct using anti-HA antibody in HCT-116 and SW480 cell line models.
Western blots were performed in triplicate. (E, Right) Quantification of three independent replicates to evaluate the percentage of −1 PRF in each cell line
model. The data represent the fraction between the intensity of the dual GST protein band (upper band) against the sum of intensities of the dual GST
protein and single GST protein (lower band). Statistical differences among proportions were calculated using an unpaired two-tailed Student’s t test.
*P < 0.05.







































the experimentally induced depletion of TYW2 in HCT-116 cells
altered the levels of 2,370 transcripts, mostly inducing transcript
down-regulation (in 86%; 2,046 of 2,370) (Fig. 3A). Gene set
enrichment analysis (GSEA) using Gene Ontology (GO) signa-
ture collections in this set of down-regulated transcripts dem-
onstrated an overrepresentation of GO biological processes
related to cell migration (e.g., “locomotion,” “cell motility,”
“biological adhesion”) (Fig. 3B). The transcripts down-regulated
on TYW2 CRISPR/Cas9 deletion were also commonly down-
regulated in those colorectal cell lines in which the TYW2 en-
zyme was naturally silenced by promoter CpG island hyper-
methylation (SI Appendix, Fig. S5). Among the down-regulated
transcripts, 109 (SI Appendix, Table S1) were included in a da-
tabase of computationally predicted eukaryotic programmed −1
PRF signals (PRFdb) (29) and contained at least one predicted
slippery sequence with UUUU/C, the codon decoded by tRNAPhe
and thus regulated by the hypermodification of G37. Importantly,
these transcripts with the −1 PRF signal and the UUUU/C se-
quence were significantly enriched among all down-regulated
transcripts compared with up-regulated transcripts and all the
genes included in the PRFdb database (Fig. 3C). Serving as an
important negative control, the transcripts with slippery sequences
containing AAAA/G, the codon for another frameshift-related
tRNA (tRNALys), were not enriched in the transcripts down-
regulated on TYW2 loss (Fig. 3C). In a similar manner, and as
an additional negative control, transcripts that did not contain the
UUU or UUC codons were not enriched in this down-regulated
group (SI Appendix, Fig. S6). Interestingly, the proteins encoded
by the down-regulated transcripts with the −1 PRF signal fre-
quently interacted with proteins derived from the down-regulated
transcripts without the motif (SI Appendix, Fig. S7), an event po-
tentially affecting RNA fate. Thus, the 109 transcripts identified
constitute bona fide candidates for direct targeting by TYW2
epigenetic loss in the colon cancer cells.
Among the identified TYW2 targets, we selected the round-
about guidance receptor 1 (ROBO1) for further validation and
study. ROBO1 was selected because it is reportedly lost in some
colorectal tumors (30, 31) and because of its proposed role as an
inhibitor of cell migration and epithelial-to-mesenchymal tran-
sition (EMT) (32, 33). We first validated the RNA expression
levels observed in the RNA-seq approach by quantitative real-
time RT-PCR, and found that the TYW2 unmethylated/expressing
HCT-116 and SW480 cells expressed the ROBO1 transcript,
whereas CRISPR/Cas9-mediated inactivation of TYW2 induced
the loss of ROBO1 transcript levels (Fig. 3D). This finding was also
mirrored at the protein level by Western blot analysis showing that
ROBO1 protein was present in the wild-type HCT-116 and
SW480 cells, whereas it was lost on experimental depletion of
TYW2 (Fig. 3D). The reverse profile of ROBO1 was observed in
TYW2 hypermethylated HT-29 cells; the recovery of TYW2 ex-
pression by transfection raised the RNA and protein levels of
ROBO1 compared with cells transfected with the empty vector
(Fig. 3D). Remarkably, using actinomycin D (Fig. 3E) and alpha-
amanitin (SI Appendix, Fig. S8) chase assays, we demonstrated a
loss of ROBO1 transcript stability on TYW2 CRISPR/Cas9 dele-
tion in HCT-116 and SW480 cells (Fig. 3E and SI Appendix, Fig.
S8), but increased ROBO1 transcript stability on TYW2 trans-
fection in HT-29 cells (Fig. 3E and SI Appendix, Fig. S8), thus
supporting the role of TYW2 in the regulation of ROBO1mRNA.
We considered that the reduced stability of ROBO1 mRNA
might be associated with NMD (34, 35) induced by the ribosome
frameshifting originating at a premature stop codon located 52
nt upstream of the subsequent exon-exon junction. To test this
idea, we used siRNA targeting UPF1 to deplete the RNA helicase
responsible for initiating NMD (34, 35). We observed that the
inhibition of NMD activity in all the cell line models with TYW2
loss (i.e., the CRISPR/Cas9-depleted HCT-116 and SW480 cells
and the hypermethylated HT-29 cells) resulted in up-regulation of
ROBO1 levels (Fig. 3F), indicating that NMD contributes to the
loss of ROBO1 in TYW2-deficient cells. As endogenous positive
controls for the assay, we used transcripts reportedly targeted by
NMD inhibition (36) (SI Appendix, Fig. S9). As an internal con-
trol, we did not observe any changes in RNA stability and NMD
assays for transcripts that did not change on TYW2 loss in the
RNA-seq analyses (SI Appendix, Fig. S10 A–C). Finally, we further
assessed the impact of TYW2 loss in the generation of ROBO1
frameshifting events by cloning the predicted slippery and stimu-
latory sequences of ROBO1 in the produced dual luciferase vector
(Fig. 2D), as described in SI Appendix, Fig. S11. We observed that
the CRISPR/Cas9-mediated loss of TYW2 caused decreased
firefly luciferase activity for ROBO1 compared with the wild-type
cells (Fig. 3G). In the opposite model, TYW2 restoration by
transfection in the hypermethylated HT-29 cells increased firefly
activity for ROBO1 (Fig. 3G). Importantly, and to ensure that
differences in reading frame maintenance between conditions
were due to specific slippage of tRNAPhe, we also generated a
luciferase reporter for ROBO1 harboring a mutation in the phe-
nylalanine codons in the slippery heptamer (SI Appendix, Fig.
S11). This mutation abolished the effect of TYW2 CRISPR/Cas9
deletion (HCT-116 and SW480 KO cells) or TYW2 epigenetic
silencing (HT-29 hypermethylated cells) on firefly activity
(Fig. 3G), similar to the action observed in the TYW2-expressing
cells such as the unmethylated wild-type HCT-116 and SW80 cells
or the methylated HT-29 cells in which TYW2 expression was
restored by transfection (Fig. 3G). Thus, the loss of the multi-
faceted cancer gene ROBO1 on TYW2 epigenetic inactivation
provides an illustrative example of how alterations of tRNA
chemical modifications might contribute to tumorigenesis.
TYW2 Epigenetic Inactivation Highlights Early-Stage Primary Colorectal
Tumors with Poor Clinical Outcome. Having demonstrated the pres-
ence of TYW2 promoter CpG island hypermethylation-associated
transcriptional silencing and its role in the generation of hypo-
modified guanosine in tRNAPhe and ribosome frameshift-associated
RNA degradation, we studied if TYW2 epigenetic loss in primary
colorectal carcinoma had any impact on outcome in these pa-
tients. To do so, we data-mined the colorectal carcinoma cases
from the TCGA effort in which we had previously identified the
presence of TYW2 hypermethylation (Fig. 1B) and associated si-
lencing (Fig. 1C) for the 371 available tumors with complete
clinical information. For the entire population of colorectal tu-
mors, TYW2 promoter hypermethylation showed a trend toward
an association with poor overall survival, but this was not statis-
tically significant (P = 0.460, log-rank test) (SI Appendix, Fig. S12).
However, when subdivided by stages, colorectal cancer patients
with early-stage disease (n = 184, stage I and II) harboring TYW2
epigenetic inactivation showed significantly reduced overall sur-
vival (hazard ratio [HR] = 2.984; 95% confidence interval [CI] =
1.26 to 7.08; P = 0.009, log-rank test) (Fig. 4A). Most importantly,
multivariate Cox regression analysis identified TYW2 hyper-
methylation as an independent predictor of shorter overall survival
in early-stage colorectal cancer (HR = 2.69; 95% CI = 1.13 to 6.41;
P = 0.026) (Fig. 4B) compared with other patient characteristics
that also have been associated with the clinical outcome (Fig. 4B).
Reinforcing these data, similar results were obtained when we
interrogated TYW2 expression levels in the same TCGA colo-
rectal cohort. For the entire population of colorectal cancer
patients, low TYW2 expression levels showed a trend toward its
association with poor overall survival, but this was not statistically
significant (P = 0.320, log-rank test) (SI Appendix, Fig. S13A).
However, when subdivided by stage, early-stage colorectal cancer
patients with TYW2 low expression levels showed significantly
reduced overall survival (HR = 4.78; 95% CI = 2.03 to 11.27; P <
0.001, log-rank test) (SI Appendix, Fig. S13B). As was shown for
TYW2 DNA methylation (Fig. 4B), multivariate Cox regression
analysis identified low TYW2 expression as an independent

















































predictor of shorter overall survival in early-stage colorectal can-
cer (HR = 4.09; 95% CI = 1.71 to 9.79; P = 0.002) compared with
other patient characteristics that also have been associated with
clinical outcome (SI Appendix, Fig. S13C).
These results could suggest that TYW2 hypermethylation in
patients with early-stage colorectal cancer might pinpoint those
tumors that, even at this early stage, contain transformed cells
that are more prone to escape from the primary site and dissem-
inate the disease. To check this, we went back to our colorectal
cancer cell line models to assess their cellular migration capacities.
Using a Transwell assay, we found that CRISPR/cas9-mediated
deletion of TYW2 in the unmethylated and expressing HCT-116
and SW480 colon cancer cell lines induced a significant increase in
the migration potential of the obtained TYW2-deficient cells
(Fig. 4C). Most importantly, we wondered whether this type of
cellular reprogramming was occurring on TYW2 loss in epithelial
tumors such as colon cancer, in which the migration, cellular de-
tachment, and invasion capacities involve the EMT (37, 38).
Most molecular pathways controlling the EMT converge in






Fig. 3. Transcriptomic identification of transcripts undergoing degradation on ribosome frameshift-mediated RNA decay and characterization of the ROBO1
candidate. (A) Volcano plot summarizing the results of the RNA-seq experiment to find differentially expressed transcripts in TYW2 CRISPR/Cas9-depleted HCT-116
cells compared with wild-type HCT-116 cells. (B) GO analysis of Biological Process categories in the transcripts down-regulated on TYW2 depletion in HCT-116 cells
shows enrichment of GO Biological Process categories related to cell migration, including “locomotion,” “cell motility,” and “biological adhesion.” (C) Down-
regulated transcripts in TYW2 KO cells are enriched in −1 PRF sites containing at least one UUUU/C slippery sequences that are present in tRNAPhe (Left); however, no
enrichment is observed for transcripts containing AAAA/G slippery sequences, the codon for tRNALys (Right). Statistical differences among proportions were cal-
culated using Fisher’s exact test. ns, not significant; *P < 0.05. (D) ROBO1 mRNA and protein levels in the studied experimental models. (Left) TYW2 CRISPR/Cas9
depletion in HCT-116 and SW480 cells down-regulated ROBO1 mRNA as determined by qRT-PCR. (Right) Western blot assay showing the ultimate loss of ROBO1
protein in the TYW2 KO cells. In the opposite model, TYW2 transfection-mediated recovery in HT-29 cells raised ROBO1 transcript and protein levels. For all cases, the
qRT-PCR data shown represent the mean ± SD of at least three biological replicates analyzed using an unpaired two-tailed Student’s t test. ***P < 0.001. (E) RNA
stability determination by the actinomycin D chase assay. A reduction in ROBO1 transcripts levels is observed on CRISPR/Cas9-mediated deletion of TYW2 HCT-116
and SW480 cells, but not in wild-type cells. In the reverse experiment, TYW2 transfection-mediated restoration in HT-29 cells stabilized ROBO1 transcript levels. For all
cases, data shown represent the mean ± SD of at least four biological replicates analyzed using the unpaired two-tailed Student’s t test at each time point. (F)
Nonsense-mediatedmRNA decay inhibition using a siRNA against UPF1 in TYW2 CRISPR/Cas9-depleted HCT-116 and SW480 cells and in empty vector (EV) transfected
HT-29 cells resulted in ROBO1mRNA up-regulation as assessed by qRT-PCR. Data shown represents the mean ± SD of biological triplicates analyzed by unpaired two-
tailed Student’s t test. *P < 0.05; **P < 0.01. (G) In vitro assay tomeasure PRF events at the cloned ROBO1mRNA containing the slippery and stimulatory sequences in
the generated dual luciferase vector. HCT-116 and SW480 cells harboring CRISPR/Cas9 deletion of TYW2 showed a reduction in firefly luciferase activity compared
with wild-type cells. In the reverse model, TYW2 transfection-mediated recovery in HT-29 cells increased firefly activity. No differences in firefly activity between
conditions were observed when phenylalanine codons of the slippery heptamer were mutated to leucine. ROBO1WT, wild-type phenylalanine codons; ROBO1MUT,
mutant-introduced leucine codons. P values correspond to two-tailed unpaired Student’s t test. ns, not significant; *P < 0.05; **P < 0.01.







































structure (37, 38), whereas expression of vimentin is a hallmark of
mesenchymal features (37, 38). In this regard, we found that TYW2
CRISPR/Cas9-mediated deletion in both HCT-116 and SW480
colon cancer cells induced down-regulation of E-cadherin and up-
regulation of vimentin (Fig. 4D). Interestingly, and in line with the
role of TYW2 loss in ROBO1 down-regulation (Fig. 3 D–G) and in
the proposed EMT inhibitory activity of this protein (32, 33), res-
toration of ROBO1 expression by transfection in the TYW2
CRISPR/Cas9-deleted HCT-116 and SW480 cells rescued the phe-
notype, inducing the opposite effect with E-cadherin up-regulation
and vimentin down-regulation (SI Appendix, Fig. S14 A and B).
CRISPR/cas9-mediated deletion of TYW2 did not change the cell
cycle, as assessed by BrdU and 7AAD incorporation, p21 expression
as a marker of cell arrest, or apoptosis measured by PARP cleavage
(SI Appendix, Fig. S15 A–C). Thus, TYW2 loss is associated with
increased migration capacity and the emergence of EMT features,
both of which have central roles in metastasis development, the
leading cause of cancer-associated mortality. These observations are
in line with the identified poor clinical outcomes of colorectal cancer
patients with TYW2 hypermethylation-associated inactivation.
Discussion
tRNAs are extremely critical biological molecules that, working
together with the ribosomes, allow translation of the genetic
code into amino acids. In humans, there are 47 different types of
tRNAs for 20 standard amino acids, in addition to selenocysteine
(39). The amount of each tRNA is tightly controlled to match the
codon usage of mRNAs to optimize protein expression according
to the cellular necessities. For many years, it was thought that
tRNAs were passive bystanders in cellular transformation, and
Fig. 4. TYW2 epigenetic loss is associated with early-stage primary colorectal tumors with poor clinical outcome. (A) Kaplan–Meier curve showing that the
presence of TYW2 hypermethylation in patients with early-stage colorectal cancer (n = 184) was significantly associated with shorter overall survival (P =
0.009). Green line, unmethylated cases; red line, methylated cases. **P < 0.01. (B) Forest plot representation of the Cox proportional hazard regression models
demonstrating that TYW2 hypermethylation is an independent prognostic factor of poor overall survival in patients with early-stage colorectal cancer (HR =
2.69; 95% CI = 1.13 to 6.41; P = 0.026). ns, not significant; *P < 0.05; (C) Transwell assay to determine cell migration capability in the studied models. HCT-116
and SW480 cells carrying the CRISPR/Cas9 deletion of TYW2 showed a significant increase in the number of migrated cells after 48 h compared with wild-type
cells. Representative images of the Transwell membrane staining are shown. P values are those associated with an unpaired two-tailed Student’s t test. *P <
0.05. (D) Assessment of EMT features in the studied models using qRT-PCR levels of the E-cadherin (epithelial) and vimentin (mesenchymal) markers. The KOs
of TYW2 in the HCT-116 and SW480 cell lines showed a combined decrease in E-cadherin expression and enhancement Vimentin levels compared with wild-
type cells, a transcript profile suggestive of the acquisition of EMT features. Data shown represent the mean ± SD of at least three biological replicates and
were analyzed using an unpaired two-tailed Student’s t test. *P < 0.05; **P < 0.01; ***P < 0.001.

















































that changes in tRNA levels were simply a consequence of the
high proliferative status of tumoral cells. However, an increasing
amount of new data show that tRNA might play an active role in
tumorigenesis (40, 41). These results include, among others, the
presence of mitochondrial tRNA mutations in cancer cells (42),
the antiapoptotic activity of tRNAs (43), and the detection of
tRNA derivatives in transformed cells that exert oncogenic or
tumor-suppressor functions (44, 45).
Another important twist involving tRNAs in cancer origin and
development is the recognition that an aberrant pattern of chem-
ical modifications in the tRNA molecule occurs in neoplasia,
causing altered protein translation (1, 10). These findings can now
be categorized within the emerging field of epitranscriptomics,
defined as the chemical modifications that affect RNA activity.
This area is booming because RNA modifications seem to play an
essential role in cellular differentiation (46) as well as in tumori-
genesis (1, 47). Human RNAs are modified in many ways (e.g.,
5-methylcytosine, N6-methyladenosine, N1-methyladenosine, pseu-
douridine, etc.) (48), and disruptions of the proteins involved in
adding, removing, or binding to these chemical marks are being
identified in human cancers (49), such as the ribosomal RNA
modifiers DKC1 (50) and NSUN5 (51). In this regard, tRNA itself
constitutes one of the most heavily modified molecules, including
some highly specific nucleotides (6). Examples of tRNA modifiers
involved in carcinogenesis include ELP3, which is up-regulated in
different tumor types and acts on theWnt pathway (52) and also has
been related to metastasis formation (53); the tRNA methyl-
transferase 9B, which has been proposed to exert a role in tumor
suppression (54); and the tRNA methyltransferase NSUN2, which
undergoes gene amplification-associated overexpression in human
tumors (55). Interestingly, modifications within the anticodon stem-
loop at position 37 of tRNA is crucial for a correct base pairing
interaction (56), and deficient hypermodification of G37 in tRNA-
Phe, without any evident cause, was reported in cancer models de-
cades ago (17–19). Here we demonstrate that the generation of
hypomodified G37 in tRNAPhe is due to the cancer-specific epige-
netic inactivation of the tRNA- modifying enzyme TYW2.
Promoter CpG island hypermethylation-associated silencing
of TYW2 was observed across a wide spectrum of human cancer
types, with colorectal tumors the most common type of tumor in
which this epigenetic defect was identified. Most importantly, the
loss of TYW2 was associated not only with the lack of hyper-
modified forms of G37 (e.g., OHyW, o2yW), but also with in-
creased ribosome frameshift, leading to transcript degradation.
The transcriptomic assay showed that numerous RNAs were
targeted by this tumor-specific event induced on TYW2 silenc-
ing. The tumor suppressor ROBO1 is a robust example of key
genes that can be hampered by this process. Even more impor-
tant from the clinical side, the DNA methylation-linked loss of
TYW2 was associated with poor clinical outcome in colorectal
cancer patients at early stages of the disease. Thus, TYW2 could
be proposed as a biomarker of early dissemination for those
tumors that at first glance seem confined to the primary site but
in reality might have escaped from its original niche. These re-
sults could be linked to the observed appearance of higher mi-
gration rates and mesenchymal features in those cancer cells
harboring TYW2 epigenetic silencing. Given the emergence of
many epigenetic drugs that restore the activity of genes inacti-
vated by DNA hypermethylation (24), it is also tempting to
speculate that the use of inhibitors of DNA methylation would
rescue TYW2 deficiency, restoring ribosome and RNA base
pairing, and avoid the migration-prone features of these cells,
thereby reducing the mortality of the identified high-risk patients
that present with an otherwise apparently localized disease.
Materials and Methods
The materials and methods used in this study are summarized here; more
detailed information is available in SI Appendix, Materials and Methods. The
sequences of all primers, as well as references for all antibodies, reagents
and commercial assays, are provided in SI Appendix, Table S2.
DNA Methylation Analyses. Gene promoter DNA methylation status was de-
termined by DNAmethylationmicroarrays and bisulfite genomic sequencing.
Expression Analyses. RNA expression was assessed by qRT-PCR, and protein
expression was determined by Western blot analysis.
TYW2 Cellular Models. In unmethylated HCT-116 and SW480 cell lines, TYW2
expression was abolished using the CRISPR/Cas9 system as described previ-
ously (57). For stable TYW2 restoration in the hypermethylated HT-29 cell
line, the TYW2 cDNA sequence was cloned into pLVX-IRES-ZsGreen plasmid
(Clontech) and delivered using lentivirus containing this construct.
tRNA Nucleosides LC-MS. tRNA from cellular models were extracted and
digested, and nucleosides were analyzed by liquid chromatography-mass
spectrometry as described previously (26).
−1 PRF Evaluation. −1 PRF events were evaluated using a dual luciferase
reporter as described previously (27). In brief, Renilla and firefly luciferases
were cloned into the pcDNA4 T/O vector, separated by the slippery sequence
of interest. In the event of a −1 PRF event, the new reading frame will
generate a premature stop codon, and firefly activity will be abolished.
RNA-Seq. Total RNA from wild-type and CRISPR/Cas9-mediated TYW2 KO
HCT-116 cells was used for RNA-seq analyses. Genes were considered to be
differentially expressed when the log2 fold change was <−1.0 or >1.0 and the
adjusted P value was < 0.05. GO biological processes gene sets included in the
GSEA signature database were used to perform an overrepresentation analysis
on the down-regulated transcripts. Coding genes were queried to the PRFdb
(29) and interrogated for the presence of putative slippery sequences.
Migration Assays. Cell migration capacity was assessed by a Transwell assay.
Cell Cycle and Apoptosis Assays. The cell cycle was assessed bymeasuring BrdU
incorporation and 7AAD staining, by immunoblotting of p21 and PARP cleavage.
Statistics. Spearman’s correlation, unpaired Student’s t test, or Fisher’s exact
test were used as appropriate. Kaplan–Meier plots and the log-rank
(Mantel–Cox) test were used to estimate overall survival. P < 0.05 was con-
sidered to indicate statistical significance.
Data Availability.All study data are included in themain text and SI Appendix.
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